GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Saxagliptin

Local RX List renal extractBase record retrieved 2026-09-05See the evidence for this drug2 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Cautions / source differences (1)

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (2)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use
Do not silently exchange CrCl and indexed eGFR thresholds

The retained original source uses a CrCl threshold; this RX mirror describes an indexed-eGFR threshold. They are not the same measurement.

Before applying: Verify the controlling product label and renal method before selecting a threshold. Older comments remain attributed.

Also check: Do not silently exchange CrCl and indexed eGFR thresholds

Rxlist source

GlobalRPh RX List - ONGLYZA

Product / population
Saxagliptin - ONGLYZA tablets; selected renal passages, not a complete prescribing monograph.
Renal measure
eGFR in mL/min/1.73 m2; preserve body-surface-area indexing.

RX mirror: this is not independent corroboration of its underlying label. Check dated-label and formulation limitations.

Current exact official saxagliptin label was not recovered in this release; mirror currency and threshold reconciliation remain review tasks.

Renal dosing, restrictions and evidence limits

The retrieved RX label mirror uses eGFR, not the older local CrCl cutoff: below 45 mL/min/1.73 m2, use 2.5 mg orally once daily, including ESRD on hemodialysis. Give after hemodialysis; peritoneal dialysis was not studied. At eGFR >=45, the renal recommendation is the same as for normal function. Assess kidney function before starting and as clinically indicated. The preserved CrCl <=50 statement and this indexed-eGFR <45 statement must remain separately attributed, not combined into one threshold.

Source revision: Source revision date not established in selected retrieval. | Retrieved: 2026-09-09. Retrieval date is not the revision date.

Source: https://globalrph.com/rx-list/onglyza-drug/

Scope: Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
GlobalRPh RX List

GlobalRPh RX List - ONGLYZA

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Saxagliptin - ONGLYZA tablets; selected renal passages, not a complete prescribing monograph.

Renal method: eGFR in mL/min/1.73 m2; preserve body-surface-area indexing.
Retrieved: 2026-09-09

Read local renal resultOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Do not silently exchange CrCl and indexed eGFR thresholds

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds
Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceRead 1 difference / caution notesClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

renal measure and currency

Do not silently exchange CrCl and indexed eGFR thresholds

The retained original source uses a CrCl threshold; this RX mirror describes an indexed-eGFR threshold. They are not the same measurement.

How to use this: Verify the controlling product label and renal method before selecting a threshold. Older comments remain attributed.

GlobalRPh RX List - ONGLYZA

Source-specific interpretation; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

New source summary - independent clinical review pending. Summaries of the identified label sections are included locally. Source import and numeric transcription checks are not independent two-reference validation. Do not treat this card as an approved institutional dosing protocol.

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeGlobalRPh RX List - ONGLYZA
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

The historical CrCl cutoff and estimation-method discussion are preserved, not relabeled as a current eGFR-based FDA protocol.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/saxagliptin/

Mechanism and indication

Competitive DPP-4 inhibition slows inactivation of meal-released GLP-1/GIP, supporting glucose-dependent insulin release and reducing fasting/postprandial glucose. GLP-1 also reduces glucagon and hepatic glucose output. In type 2 diabetes GLP-1 concentrations are reduced but insulin responsiveness to GLP-1 persists.

ONGLYZA is described as adjunctive to diet/exercise for adult type 2 diabetes, alone or in combination. Not for type 1 diabetes or diabetic ketoacidosis.

GRPH-saxagliptin-01 · Source section: Mechanism and indicationRenal section finder

Usual Dosing (Adults)

2.5 or 5 mg once daily, without regard to meals.

GRPH-saxagliptin-02 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

Original CrCl-based source: above 50 mL/min, no adjustment; at or below 50 or ESRD requiring HD, 2.5 mg once daily. Give after hemodialysis. Peritoneal dialysis was not studied.

Assess renal function before starting and periodically thereafter. The source mentions Cockcroft-Gault or MDRD estimation from serum creatinine; these methods/units should not be assumed interchangeable in a current product-label algorithm.

GRPH-saxagliptin-03 · Source section: Renal DosingRenal section finder

Hemodialysis

The renal section provides 2.5 mg daily after HD; the separate HD heading supplies no further text.

GRPH-saxagliptin-04 · Source section: HemodialysisRenal section finder
Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist

GlobalRPh RX List - ONGLYZA

Open original reference

Open / share this exact local source

GlobalRPh-hosted RX List · Saxagliptin - ONGLYZA tablets; selected renal passages, not a complete prescribing monograph.

Renal method: eGFR in mL/min/1.73 m2; preserve body-surface-area indexing.
Source date: Source revision date not established in selected retrieval.
Retrieved: 2026-09-09

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.
Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected source text imported locally; independent clinical review pending. Not a complete prescribing monograph.

Renal dosing, restrictions and evidence limits

The retrieved RX label mirror uses eGFR, not the older local CrCl cutoff: below 45 mL/min/1.73 m2, use 2.5 mg orally once daily, including ESRD on hemodialysis. Give after hemodialysis; peritoneal dialysis was not studied. At eGFR >=45, the renal recommendation is the same as for normal function. Assess kidney function before starting and as clinically indicated. The preserved CrCl <=50 statement and this indexed-eGFR <45 statement must remain separately attributed, not combined into one threshold.

RDM53-rxlist-saxagliptin-08e41e8c47-C1 · Source locator: Dosage in patients with renal impairment.

Source-specific limits

Current exact official saxagliptin label was not recovered in this release; mirror currency and threshold reconciliation remain review tasks.

Source identity and provenance
Source family
product_label_mirror
Source
https://globalrph.com/rx-list/onglyza-drug/
Retrieved
2026-09-09
Renal-function method
eGFR in mL/min/1.73 m2; preserve body-surface-area indexing.
Source date/version
Source revision date not established in selected retrieval.
Hash meaning
SHA-256 of local authored summary only; not original HTML, PDF or SPL bytes.
Local summary SHA-256
e8fec465fe5afd15ca648ce919c9b1b548a9b72a4d494ca9e52b2d5788542156

Provenance and preservation

Additional summaries stored on this page: 0 official-label, 1 RX List, 0 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/saxagliptin/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph individual
Local text SHA-256
9d1d3f3b5cdf1de54940df51434b0560921727131fdba2fc0034b1a80b93a167
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report